EUVIMEDEUVIMED entdecken
Multizentrische Studie

Extended interval dosing with ocrelizumab in multiple sclerosis

Frederik Novak iD, Hamza Mahmood Bajwa, Kamilla Østergaard, Jonas Munksgaard Berg, Jonna Skov Madsen, Dorte Aalund Olsen, Inga Urbonaviciute, Zsolt Illes, Morten Leif Stilund, Jeppe Romme Christensen, Stephan Bramow, Finn Sellebjerg und 1 weitere

Multiple Sclerosis Journal · 2024-06 · 30 (7) · 847-856

DOI: 10.1177/13524585241245296 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Multiple Sclerosis Journal, online erschienen am 22.04.2024. Verfasst von Frederik Novak und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Esbjerg Hospital, University Hospital of Southern Denmark, Esbjerg, Denmark. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Immunologic Factors. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study investigates clinical and biomarker differences between standard interval dosing (SID) and extended interval dosing (EID) of ocrelizumab therapy in multiple sclerosis (MS).

Methods

This is a prospective, double-arm, open-label, multi-center study in Denmark. Participants diagnosed with MS on ocrelizumab therapy >12 months were included ( n = 184). Clinical, radiological, and blood-based biomarker outcomes were evaluated. MRI disease activity, relapses, worsening of neurostatus, and No Evidence of Disease Activity-3 (NEDA-3) were used as a combined endpoint.

Results

Out of 184 participants, 107 participants received EID (58.2%), whereas 77 participants received SID (41.8%). The average extension was 9 weeks with a maximum of 78 weeks. When comparing EID to SID, we found higher levels of B-cells, lower serum concentrations of ocrelizumab, and similar levels of age-adjusted NFL and GFAP in the two groups. No difference in NEDA-3 between EID and SID was demonstrated (hazard ratio: 1.174, p = 0.69). Higher levels of NFL were identified in participants with disease activity. Body mass index correlated with levels of ocrelizumab and B-cells.

Conclusion

Extending one treatment interval of ocrelizumab on average 9 weeks and up to 78 weeks did not result in clinical, radiological, or biomarker evidence of worsening compared with SID.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedImmunologic FactorsHumansFemaleMaleAdultMiddle AgedProspective StudiesBiomarkersMultiple SclerosisTreatment OutcomeMagnetic Resonance ImagingDrug Administration ScheduleMultiple Sclerosis, Relapsing-Remitting

Stichwörter der Autor:innen

Multiple sclerosisNEDA-3anti-CD20biomarkersextended dosingneuroimagingocrelizumabpersonalized medicinetreatment interval

Substanzen

ocrelizumabAntibodies, Monoclonal, HumanizedImmunologic FactorsBiomarkers

Autor:innen und Institutionen

  • Department of Neurology, Esbjerg Hospital, University Hospital of Southern Denmark, Esbjerg, Denmark.
  • Department of Regional Health Research, University of Southern Denmark, Odense, Denmark.
  • Department of Neurology, Nordsjællands Hospital, Hillerød, Denmark.
  • Department of Neurology, Hospitalsenhed Midt, Viborg, Denmark.
  • Department of Biochemistry and Immunology, Lillebaelt Hospital, University Hospital of Southern Denmark, Vejle, Denmark.
  • Department of Biochemistry and Immunology, Lillebaelt, University Hospital of Southern Denmark, Vejle, Denmark.

ORCID-Profile: Frederik Novak

Zitieren

APA

Novak, F., Bajwa, H. M., Østergaard, K., Berg, J. M., Madsen, J. S., Olsen, D. A., Urbonaviciute, I., Illes, Z., Stilund, M. L., Romme Christensen, J., Bramow, S., Sellebjerg, F., & Sejbaek, T. (2024). Extended interval dosing with ocrelizumab in multiple sclerosis. Multiple Sclerosis Journal, 30(7), 847-856. https://doi.org/10.1177/13524585241245296

Vancouver

Novak F, Bajwa HM, Østergaard K, Berg JM, Madsen JS, Olsen DA, et al. Extended interval dosing with ocrelizumab in multiple sclerosis. Multiple Sclerosis Journal. 2024;30(7):847-856. doi:10.1177/13524585241245296

BibTeX
@article{Novak2024,
  author = {Novak, Frederik and Bajwa, Hamza Mahmood and Østergaard, Kamilla and Berg, Jonas Munksgaard and Madsen, Jonna Skov and Olsen, Dorte Aalund and Urbonaviciute, Inga and Illes, Zsolt and Stilund, Morten Leif and Romme Christensen, Jeppe and Bramow, Stephan and Sellebjerg, Finn and Sejbaek, Tobias},
  title = {Extended interval dosing with ocrelizumab in multiple sclerosis},
  journal = {Multiple Sclerosis Journal},
  year = {2024},
  volume = {30},
  number = {7},
  pages = {847--856},
  doi = {10.1177/13524585241245296}
}
Kostenlos starten →